Gene therapy total deal value at Phase 2 in 2026

Gene therapy deals are structured to reflect the curative potential of single-administration treatments. With upfront payments of $253M, these deals include significant regulatory and commercial milestones tied to durable efficacy data and market access.

Based on analysis of 600+ biopharma licensing deals from 2020-2026